Clinical Characteristics of Steatotic Liver Disease Categories in a Large Cohort of Japanese Health Checkup Participants

• Published in: Gastro hep advances Vol. 3; no. 8; pp. 1148 - 1156
• Main Authors: Kamada, Yoshihiro, Fujii, Hideki, Suzuki, Yuichiro, Sawada, Koji, Tatsuta, Miwa, Maeshiro, Tatsuji, Tobita, Hiroshi, Tsutsumi, Tsubasa, Akahane, Takemi, Hasebe, Chitomi, Kawanaka, Miwa, Kessoku, Takaomi, Eguchi, Yuichiro, Syokita, Hayashi, Nakajima, Atsushi, Kamada, Tomoari, Yoshiji, Hitoshi, Kawaguchi, Takumi, Sakugawa, Hiroshi, Morishita, Asahiro, Masaki, Tsutomu, Ohmura, Takumi, Watanabe, Toshio, Yoda, Yoshioki, Enomoto, Nobuyuki, Ono, Masafumi, Fuyama, Kanako, Okada, Kazufumi, Nishimoto, Naoki, Ito, Yoichi M., Takahashi, Hirokazu, Sumida, Yoshio
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01-01-2024; Elsevier
• Subjects: Alcohol Intake; FIB-4 Index; Metabolic Dysfunction; Original Research—Clinical; Steatotic Liver Disease; Systolic Blood Pressure; Metabolic Dysfunction; AST; NAFLD; Systolic Blood Pressure; ALT; DM; MASLD; BP; Alcohol Intake; FIB-4 Index; Steatotic Liver Disease; GGT; MetALD; ALD; HCV; BMI
• ISSN: 2772-5723; 2772-5723
• DOI: 10.1016/j.gastha.2024.08.006

The clinical characteristics and risk factors involved in the development of liver fibrosis in the subtypes of steatotic liver disease (SLD) remain unknown. We examined the clinical characteristics of SLD subtypes using a large Japanese cohort.
We performed a cross-sectional analysis (total n = 108,446). In this cohort, SLD was diagnosed by ultrasonography. Individuals with none of the cardiometabolic risk factors were excluded.
According to their nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) status based on the database, participants with cardiometabolic criteria were allocated to the MASLD, MASLD with increased alcohol intake (MetALD), and alcohol-associated liver disease (ALD) with metabolic dysfunction groups. Of 30,857 subjects with SLD, 21,488 (69.6%) had NAFLD, and 20,922 (67.8%) had MASLD. There were few differences in the clinical characteristics between NAFLD and MASLD. After adjustment for clinical variables, we found that male patients with MetALD [odds ratio (OR) 2.26; 95% confidence interval (CI) 1.87–2.84] and ALD with metabolic dysfunction (OR 3.92; 95% CI 2.85–5.39) had a significantly higher risk for advanced liver fibrosis (diagnosed by Fibrosis-4 (FIB-4) index >2.67) compared to those with MASLD. In female patients with ALD, metabolic dysfunction (OR 5.80; 95% CI 2.51–13.4) and systemic blood pressure of ≥130 mmHg were significant risk factors for high FIB-4 (males: OR 3.38, 95% CI 2.51–4.55; females: OR 4.34, 95% CI 2.66–7.07, P < .001).
Alcohol intake and systolic blood pressure are independent contributors to liver fibrosis progression assessed by FIB-4 in SLD.